Stocks Health care ASMB
NASDAQ · Health careAssembly Biosciences, Inc. (ASMB)
Assembly Biosciences, Inc. brought in $74.8M of revenue over the twelve months to June 30, 2026, up 125.1% from a year earlier. It posted a net loss of $42K. In fiscal 2025 capital spending exceeded operating cash flow by $41.2M. At June 30, 2026 it held $32.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Assembly Biosciences, Inc.
- Net worth
- Assembly Biosciences, Inc. has a market value (market cap) of $434.7M at the latest share price, and shareholders' equity of $305.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $72.3M (+153.5% year on year), with a net loss of $6.1M. Over the 12 months to June 30, 2026: revenue $74.8M, net loss $42K.
- Cash flow
- In fiscal 2025 operations used $41.1M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Assembly Biosciences, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
What Assembly Biosciences, Inc. does
Assembly Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ASMB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $72.3M | -$6.1M | -$0.55 | -$41.2M |
| 2024 | $28.5M | -$40.2M | -$6.69 | -$51.1M |
| 2023 | $7.2M | -$61.2M | -$13.38 | $22.5M |
| 2022 | $0 | -$93.1M | -$23.08 | -$84.6M |
| 2021 | $6.3M | -$129.9M | -$36.06 | -$96.5M |
| 2020 | $79.1M | -$62.2M | -$21.04 | -$63.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ASMB ranks in Health care
Latest SEC filings
What Assembly Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 20, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Quarterly results 8-K/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 39% to $13.4M versus the same quarter last year; diluted EPS -$0.20 versus -$1.33.
- August 13, 2026
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026Passive stake changed SCHEDULE 13G/A
- June 5, 2026
- May 26, 2026
- May 22, 2026
Insider trades
What the people running Assembly Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $237.6K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Okazaki Jason ACEO and President, Director | Sold | 6,133 | $120.3K |
| November 2, 2026 | Okazaki Jason ACEO and President, Director | Sold | 69 | $1.4K |
| November 2, 2026 | Gaggar AnujChief Medical Officer | Sold | 2,564 | $50.3K |
| November 2, 2026 | Gaggar AnujChief Medical Officer | Sold | 29 | $590.1 |
| November 2, 2026 | White Nicole SChief Manufacturing Officer | Sold | 2,564 | $50.3K |
| November 2, 2026 | White Nicole SChief Manufacturing Officer | Sold | 29 | $590.1 |
| November 2, 2026 | Bjorkquist Jeanette MPFO and PAO | Sold | 718 | $14.1K |
| November 2, 2026 | Bjorkquist Jeanette MPFO and PAO | Sold | 9 | $183.1 |
Who owns ASMB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Commodore Capital LP13G, passive with 3 related filers | 9.9% | August 15, 2025 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.5% | August 18, 2025 |
| Farallon Capital Management, L.L.C.13G, passive with 26 related filers | 8.1% | August 4, 2026 |
| Dapice Joshua J.13G, passive with 28 related filers | 7.8% | February 9, 2026 |
| Paradigm BioCapital Advisors LP13G, passive with 3 related filers | 7.8% | August 14, 2026 |
| JANUS HENDERSON GROUP Ltd.13G, passive | 6.9% | August 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 93 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Gilead Sciences, Inc. | 4,977,089 | +471,698 |
| Farallon Capital Management, L.L.C. | 1,604,590 | +377,000 |
| Paradigm Biocapital Advisors LP | 1,553,748 | +888,497 |
| Commodore Capital LP | 1,415,000 | +415,000 |
| RA Capital Management, L.P. | 1,020,410 | 0 |
| Jupiter Topco LLC | 849,309 | new |
| BlackRock, Inc. | 766,819 | +564,076 |
| Parkman Healthcare Partners LLC | 721,181 | +309,954 |
| Vanguard Capital Management LLC | 558,942 | +68,495 |
| Point72 Asset Management, L.P. | 460,593 | +116,488 |
| Seven Fleet Capital Management LP | 433,147 | +377,000 |
| Millennium Management LLC | 298,807 | +65,157 |
| Geode Capital Management, LLC | 280,424 | +147,453 |
| Schonfeld Strategic Advisors LLC | 242,153 | +121,653 |
| Ameriprise Financial Inc | 230,000 | new |
| DV Equities, LLC | 226,415 | new |
| Aberdeen Group plc | 207,047 | new |
| Affinity Asset Advisors, LLC | 190,000 | new |
| B Group, Inc. | 175,706 | 0 |
| State Street Corp | 171,931 | +115,242 |
Insiders
5 insiders reported holding 400,297 shares in total, about $8.5M at the last price.
| Holder | Shares |
|---|---|
| Okazaki Jason ACEO and President, Director | 195,532 |
| Delaney William E IVChief Scientific Officer | 74,035 |
| White Nicole SChief Manufacturing Officer | 59,257 |
| Gaggar AnujChief Medical Officer | 53,800 |
| Bjorkquist Jeanette MPFO and PAO | 17,673 |
Questions about ASMB
What does Assembly Biosciences, Inc. do?
Assembly Biosciences, Inc. is a company in the Health care sector, listed on NASDAQ as ASMB. Its shares trade on NASDAQ under the ticker ASMB.
What is Assembly Biosciences, Inc.'s net worth?
Assembly Biosciences, Inc. has a market value (market cap) of $434.7M at the latest share price, and shareholders' equity of $305.6M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Assembly Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $42K on revenue of $74.8M.
How much revenue does Assembly Biosciences, Inc. make?
Over the twelve months to June 30, 2026 Assembly Biosciences, Inc. reported revenue of $74.8M. That is 125.1% more than a year earlier.
When did Assembly Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from November 3, 2026.
When is Assembly Biosciences, Inc.'s next earnings report?
Assembly Biosciences, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
Similar companies
Compare ASMB with
Follow ASMB
Get an email when Assembly Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Assembly Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.